Clinical trials
Esophageal Adenocarcinoma clinical trials
Below are recruiting esophageal adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 109 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04114136RecruitingPhase 2
Study tests pembrolizumab or nivolumab plus a diabetes-like drug
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07152405RecruitingPhase 3
New drug vs. chemo for HER2+ stomach cancer
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that has spread. The goal is to see if BL-M07D1 works better than standard chemo.
Harbin, HeilongjiangAges 18–75 - NCT04939051RecruitingPhase 2
Obeticholic acid to prevent Barrett’s esophagus worsening
This Phase 2 trial tests whether obeticholic acid (a medicine) can help stop Barrett’s esophagus from getting worse. You must already be taking acid-suppressing medicine and have non-cancer Barrett’s changes, and the study checks safety and whether the lining improves or stays stable.
Kansas City, KansasAges 18 years+ - NCT05188313RecruitingPhase 3
HER2 medicines before surgery for resectable esophageal cancer
This trial tests two targeted medicines, trastuzumab and pertuzumab (HER2-blocking drugs), given before surgery for HER2-positive esophageal or stomach-esophagus junction cancer. The goal is to shrink the tumor and improve how well surgery works and outcomes after treatment.
AmsterdamAges 18 years+ - NCT07284186RecruitingPhase 1
Study of PLX-61639 for advanced SMARCA4-mutant solid tumors
This trial is testing a new drug called PLX-61639 for people with advanced solid tumors that have a specific SMARCA4 gene change. The drug aims to stop cancer growth by targeting the cells that lack this gene.
Scottsdale, ArizonaAges 18 years+ - NCT06808971RecruitingPhase 2
Perioperative drug combo for advanced stomach cancer
This study tests a combination of four drugs given before and after surgery for a type of stomach or throat-stomach cancer that can be removed. The drugs are adebrelimab (immunotherapy), nab-paclitaxel, oxaliplatin, and tegafur. The goal is to see if this combination works better than standard treatments.
BeijingAges 18–75 - NCT05370144Recruiting
Pre-surgery chemotherapy and radiation for esophagus cancer
This study tests a new pre-surgery treatment plan that combines chemotherapy with focused, shorter-course radiation for esophagus or stomach-where-it-meets-the-esophagus (GEJ) adenocarcinoma. The goal is to shrink the tumor before surgery and improve treatment outcomes.
Calgary, AlbertaAges 18–80 - NCT00288119Recruiting
Study genes in Barrett’s esophagus and esophageal cancer
This study looks at genetic (inherited) factors that may be linked to Barrett’s esophagus and esophageal cancer. It may help researchers understand why these conditions happen in some families and others do not.
Baltimore, MarylandAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT07481357RecruitingPhase 1
DA 3501 for advanced stomach or pancreatic cancer
This trial tests a new drug, DA 3501, in people with advanced stomach or pancreatic cancer that has a specific protein called CLDN18.2. It aims to see if the drug is safe and effective.
Seongnam, BundangAges 19 years+ - NCT07488676RecruitingPhase 1/Phase 2
Study of ASP546C for stomach, pancreas, and other cancers
This trial tests a new drug called ASP546C in people with certain advanced cancers that have a specific marker (CLDN18.2). It aims to see if the drug can shrink or slow tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT06199895RecruitingPhase 2
Study of paclitaxel for patients with taxane-resistant solid tumors
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
Wuhan, HubeiAges 18 years+ - NCT06161818RecruitingPhase 2
Combined therapy before surgery for lymph node-positive esophageal cancer
This trial is testing a combination of chemotherapy and radiation (called total neoadjuvant therapy) before surgery for a type of esophageal cancer that has spread to lymph nodes. The goal is to see if this approach improves outcomes.
Eindhoven, North BrabantAges 18 years+ - NCT06163729RecruitingPhase 2
Testing camrelizumab plus chemo and radiation before/after surgery for stomach-esophagus cancer
This trial tests combining the immunotherapy drug camrelizumab with chemotherapy and radiation before and after surgery for a specific type of stomach-esophagus cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18–80 - NCT04306458Recruiting
Testing robot-assisted vs standard surgery for resectable esophageal cancer
This trial compares a robot-assisted approach to a standard minimally invasive approach for surgery in people with certain types of esophageal or gastroesophageal junction cancer that can be removed. It aims to see which surgery method works better and is safer for these patients.
MainzAges 18–90 - NCT05688176Recruiting
Testing blood RNA markers for esophagus cancer and Barrett’s
This study looks for helpful “RNA markers” found in blood to improve diagnosis in people with Barrett’s esophagus or esophageal cancer. It may help doctors spot disease more reliably, but it requires specific health and treatment conditions and a planned biopsy blood sample process.
Ghent, Oost-VlaanderenAges 18 years+ - NCT06071845Recruiting
Testing a simpler sponge test for Barrett's esophagus
This study tests a new, less invasive way to collect cells from the esophagus using a small sponge on a string (called Cytosponge). It aims to see if this method can accurately detect Barrett's esophagus, a condition that can raise the risk of esophageal cancer.
Scottsdale, ArizonaAges 18–90 - NCT06962137RecruitingPhase 2
Zolbetuximab plus two chemos for CLDN18.2-positive stomach cancer
This trial tests a combination of three drugs (zolbetuximab, paclitaxel, and ramucirumab) for people with advanced stomach or esophagus cancer that has a specific protein called CLDN18.2. It may be an option if you've already had one standard treatment.
AntwerpAges 18 years+ - NCT06532734Recruiting
Barrett's Esophagus in people with purging eating disorders
This study checks if long-term purging (vomiting) in people with eating disorders can damage the tube that connects your mouth to your stomach (called the esophagus). The goal is to see how common Barrett's esophagus (a precancerous change) is in this group.
Denver, ColoradoAges 18–65 - NCT03539822RecruitingPhase 1/Phase 2
Cabozantinib and immunotherapy for advanced stomach or bowel cancers
This early-phase study tests a combination of anti-cancer pills and immune-based treatment for people with advanced stomach, esophagus, colorectal, or liver cancer. It aims to shrink tumors and see how safe the treatment is, including whether biopsy testing can help guide future care.
Westwood, KansasAges 18 years+ - NCT05642338Recruiting
Testing two sampling methods to monitor Barrett’s esophagus
This study compares two ways of taking tissue samples during endoscopy to check how Barrett’s esophagus is changing. The goal is to improve surveillance, especially for finding early precancer or early cancer changes.
Amsterdam, North HollandAges 18 years+ - NCT05753748Recruiting
Compare watchful waiting vs endoscopy treatment for Barrett’s with low-grade dysplasia
This trial compares two approaches for people with Barrett’s esophagus and low-grade dysplasia: regular monitoring versus treatment done through an endoscopy. It aims to see which approach is safer and better at preventing progression to more serious changes in the esophagus.
Los Angeles, CaliforniaAges 18–89 - NCT06523374Recruiting
Studying quality of life and cancer risk in Barrett's esophagus
This study looks at how Barrett's esophagus affects your quality of life and fear of cancer. It uses new tests to better predict who might develop esophageal cancer, so you can get the right care sooner.
Edegem, AntwerpenAges 18 years+ - NCT06687603Recruiting
Detecting Barrett's esophagus in people without heartburn
This study aims to screen for Barrett's esophagus in people who are getting a routine colonoscopy but do not have chronic heartburn. It uses a simple, non-invasive cell collection device (EsoCheck) to see if you might have Barrett's esophagus, which can increase the risk of esophageal cancer.
Aurora, ColoradoAges 50 years+
Hear when a new Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for esophageal adenocarcinoma?
- Yes. Clin2 currently lists 109 recruiting esophageal adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a esophageal adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a esophageal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8
- Metastatic Esophageal Adenocarcinoma
- Clinical Stage I Esophageal Adenocarcinoma AJCC v8
- Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Unresectable Esophageal Adenocarcinoma
- Advanced Esophageal Adenocarcinoma
- Esophageal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.